Leibowitz M D, Fiévet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J, Cullinan C A, Sparrow C P, Baffic J, Berger G D, Santini C, Marquis R W, Tolman R L, Smith R G, Moller D E, Auwerx J
Department of Molecular Endocrinology, Merck Research Laboratories, Rahway, NJ 07065, USA.
FEBS Lett. 2000 May 19;473(3):333-6. doi: 10.1016/s0014-5793(00)01554-4.
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors, which heterodimerize with the retinoid X receptor and bind to peroxisome proliferator response elements in the promoters of regulated genes. Despite the wealth of information available on the function of PPARalpha and PPARgamma, relatively little is known about the most widely expressed PPAR subtype, PPARdelta. Here we show that treatment of insulin resistant db/db mice with the PPARdelta agonist L-165041, at doses that had no effect on either glucose or triglycerides, raised total plasma cholesterol concentrations. The increased cholesterol was primarily associated with high density lipoprotein (HDL) particles, as shown by fast protein liquid chromatography analysis. These data were corroborated by the chemical analysis of the lipoproteins isolated by ultracentrifugation, demonstrating that treatment with L-165041 produced an increase in circulating HDL without major changes in very low or low density lipoproteins. White adipose tissue lipoprotein lipase activity was reduced following treatment with the PPARdelta ligand, but was increased by a PPARgamma agonist. These data suggest both that PPARdelta is involved in the regulation of cholesterol metabolism in db/db mice and that PPARdelta ligands could potentially have therapeutic value.
过氧化物酶体增殖物激活受体(PPARs)是核受体,它们与视黄酸X受体形成异二聚体,并与受调控基因启动子中的过氧化物酶体增殖物反应元件结合。尽管关于PPARα和PPARγ的功能已有大量信息,但对于表达最为广泛的PPAR亚型PPARδ,人们了解得相对较少。在此我们表明,用PPARδ激动剂L-165041处理胰岛素抵抗的db/db小鼠,在对血糖或甘油三酯均无影响的剂量下,会提高血浆总胆固醇浓度。快速蛋白质液相色谱分析表明,胆固醇升高主要与高密度脂蛋白(HDL)颗粒有关。通过超速离心分离的脂蛋白的化学分析证实了这些数据,表明用L-165041处理会使循环HDL增加,而极低密度或低密度脂蛋白无重大变化。用PPARδ配体处理后,白色脂肪组织脂蛋白脂肪酶活性降低,但用PPARγ激动剂处理则活性增加。这些数据表明,PPARδ参与db/db小鼠胆固醇代谢的调节,并且PPARδ配体可能具有治疗价值。